Oryzon Genomics Company Description

Oryzon Genomics S.A., a clinical stage biopharmaceutical company, engages in the discovery and development of epigenetics-based therapeutics for patients with cancer and CNS disorders.

Its clinical phase compounds include iadademstat (ORY-1001), a selective LSD1 inhibitor that is in Phase II trials for oncology; and vafidemstat (ORY-2001), a CNS-optimized LSD1 inhibitor, which is in Phase II trials for the treatment of CNS and psychiatric diseases.

Its product candidates also comprise ORY-3001, an LSD1 inhibitor that is in preclinical development for the treatment of non-oncological diseases.

The company was founded in 2000 and is based in Cornellà de Llobregat, Spain.

Oryzon Genomics S.A.

Country	Spain
Founded	2000
Industry	Medical - Pharmaceuticals
Sector	Healthcare
Employees	46
CEO	Carlos Manuel Arjol

Contact Details

Address: Sant Ferran 74 Cornellà de Llobregat, 08940 Spain
Phone	34 93 515 13 13
Website	oryzon.com

Stock Details

Ticker Symbol	0RDB
Exchange	London Stock Exchange
Fiscal Year	January - December
Reporting Currency	USD
ISIN Number	ES0167733015
SIC Code	2836

Key Executives

Name	Position
Carlos Manuel Arjol	Chief Executive Officer
Enric Condomines	Chief Financial Officer
Enric Condomines	Chief Operating Officer